FDA Officials Float Market-Based Ideas To Stem Drug Shortages

FDA officials are floating a new market-based approach to stem drug shortages that result from quality issues, suggesting the agency help buyers and payers in their purchase and reimbursement decisions by providing them with "meaningful manufacturing quality metrics" similar to restaurant grades or HMO scorecards.

Subscription required, click here